LittleGunner (@LittleGunner5) profile picture

AIM investments for bigger returns. Buy quality stocks early and hold. Lessons learnt every day. Don't chase the rainbows, there's normally not a pot of gold!

Joined April 2020
Photo by LittleGunner (@LittleGunner5)Photo by LittleGunner (@LittleGunner5)Photo by LittleGunner (@LittleGunner5)Photo by LittleGunner (@LittleGunner5)Photo by LittleGunner (@LittleGunner5)Photo by LittleGunner (@LittleGunner5)Photo by LittleGunner (@LittleGunner5)Photo by LittleGunner (@LittleGunner5)Photo by LittleGunner (@LittleGunner5)Photo by LittleGunner (@LittleGunner5)
Also means that multiple, senior, powerful people committed perjury at CAS. @fedpolCH get busy.
Seismic for English football. Manchester City were, in effect, accused of corporate fraud. Accused of breaching PSR and UEFA FFP on several occasions. Accused of not providing accurate player/manager payment details. Accused of not cooperating. Guilty on all but one charge
22
232
3
1,729
116,431
🚨 EXCLUSIVE: Manchester City found guilty on virtually all charges relating to breaches of Premier League financial regulations. #MCFC expected to appeal against verdict issued by independent commission. Sanctions undecided, process ongoing @TheAthleticFC nytimes.com/athletic/7049721…
109
296
16
3,274
122,320
LittleGunner retweeted
The Arsenal. Your Premier League champions.
27,603
201,661
35,303
579,894
39,671,164
LittleGunner retweeted
So today's data confirms 6k is still effective in SGC. But more importantly, below we have it (mistakenly) from the horses mouth that they're talking to Norvartis. It's always been about that PLATFORM. Stupid drop today, but not for long #AVCT – at Cape Canaveral, FL
This Post is from an account that no longer exists. Learn more
3
2
32
3,116
LittleGunner retweeted
#AVCT As I said, and as everyone knows! The science is great, we get it! We want to know how you're going to commercialise it and what the commercial road map looks like. Read the room @coughlin582 @avacta! The SP is where it is because of this. Talk commercial, not science!
#AVCT @coughlin582 If you think you can pay the next CLN in shares but the SP will recover because of anything science based you release at AACR, you are MISTAKEN A commercial plan is reqd which YOU highlighted as priority 12 mnths ago! The science aint cutting it, unfortunately!
5
4
69
9,505
LittleGunner retweeted
#AVCT Shorters are clearly back..🤔 Just sign us a small deal ffs. Third party validation is needed Ignore the 50 billion dollar value crowd ...just get us a partner who see the value in this safe and superior delivery platform to a pipeline of oncology weapons Get on with it
7
2
44
5,659
There’s 10s of deals being struck that underpin this. Can management get this under the nose of those with similar cash piles? Can they sell the upside story? It’s all getting a bit silly. Asthma 🤚🏻#AVCT
$40m upfront. 14.3m warrants (19.9% stock) $940m milestone out turn. Asthma target. 1x 22 patient Phase 2a asset. 1x preclinical asset. “Further validates platform” CEO confirmed deal discussions were progressing in April ‘24. Tuned in. #AVCT
2
1
14
5,300
#AVCT Good to see that the health authorities have agreed a lifetime dose increase of @avacta ‘s “FAP Dox” from 450 mg/m2 to 550 mg/m2, with potentially more to come. Thanks to Carlo.
2
3
49
2,954
Final sentence of each paragraph #avct
6
8
2
84
14,485
LittleGunner retweeted
Replying to @tom_the_bomb__
#avct attendance focus set on ‘investment’ rather than an opportunity to share trial results…. That’s how I read it. Questions is, are they using this event to: 1) Entice partners, 2) Announce partner, 3) Both
2
2
22
1,488
LittleGunner retweeted
Finally it's (almost) gone! The long and sorry episode which got us lumbered with the CLN is over. Enough cash to see us into 2026 and to get enough P1b data to sign a phenomenal deal or get taken out. Sell Coris for a couple of mil as well then chase the TX dream #AVCT – at Exeter, England
1
1
42
2,735
LittleGunner retweeted
Tell me you don’t get it without telling me you don’t get it 🤦‍♂️ The biggest risk facing #avct shareholders is the funding strategy. It’s not the science
1
3
22
2,041
LittleGunner retweeted
#AVCT 8.5% down on double the 3m avg. daily volume and closed v close to the daily lows. Stinks of another leaked placing To not deliver commercially following the last value destructing raise and with more than enough clinical evidence to make a deal is unacceptable @avacta
4
2
37
3,663
#AVCT - Absolutely. We had the winning lottery ticket last year and many worried where the money was coming from. The £ came from a heavily discounted placing at 50p. Still have a winning lottery ticket but let’s hope the money comes from a different source this year. Given the poor commercial ability of the board I’m not ruling out another AIM placing. Let’s pray DX sale completes this week.
1
1
16
1,597
The issue I have @coughlin582 is that we the owners of @avacta are being kept in the dark regarding a number of issues where the transparency has been unacceptable. How can any investor decide what is a fair valuation for #AVCT when we don’t know some key bits of information?
2
1
1
32
3,835
Avacta should never pay back the cln in cash. Conserve cash at all cost and every penny should go to increase pipeline value. That will more than offset dilution. Furthermoye, cash is strength at the negotiation table.. again offsetting dilution. #avct
1
1
36
5,199
LittleGunner retweeted
Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona. avacta.com/avacta-reports-pi… #AVCT
10
45
8
227
76,174
This is possibly the most consequential RNS that @avacta #AVCT has ever put out. "Our first program, AVA6000, demonstrates a four- to six-fold increase in the therapeutic index in the clinic and in preclinical models.... We are now seeing a 75-fold increase in therapeutic index with our recently announced exatecan program, AVA6103 in preclinical models, suggesting that AVA6103 could have an unprecedented safety profile in the clinic." - the maximum tolerated dose of pre|CISION exatecan (AVA6103) observed is 75 times that of conventional exatecan in a daily dosing regimen; - up to 50-fold higher warhead concentrations in the tumor versus plasma in a patient-derived xenograft model; - AVA6103 inhibits tumor growth, with complete responses noted in a preclinical treated model (N.B. multiple CRs!). This drug will obliterate the existing competition in the ADC space (notably, the currently market-leading Enhurtu and Trodelvy ADCs that use Top-1 inhibitors). And I don't mean just surpass; but properly obliterate. The company has nailed the science and the platform now. It can be used to harness immensely toxic warheads - the most potent in existence; and can be used to target as much as three quarters of all cancer cases worldwide. A truly transformational development in the field of oncology. The UK market may not see it immediately (especially given immediate-term Budget concerns and silly games over the HCI bond), but the world of Big Pharma will. I am convinced that Avacta will be acquired within 12 months now - possibly much sooner.
Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona. avacta.com/avacta-reports-pi… #AVCT
20
44
2
302
42,511
#AVCT The doomsayers are back, this time regarding the commercial strategy. This is being worked on as CC has discussed. Darlene likely plays a role in a Nasdaq list with insto /pharma investment, imo. In the mean time, ample cash to see us to Dx disposal which extends runway
4
2
31
4,208